echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Reding Pharmaceutical PD-1 has been approved to conduct clinical trials of tube squamous cell carcinoma.

    Reding Pharmaceutical PD-1 has been approved to conduct clinical trials of tube squamous cell carcinoma.

    • Last Update: 2020-09-18
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    INCMGA00012 is a PD-1 monoantiba, has been approved for 4 clinical trials, adaptive diseases for stomach cancer (GC) or gastroesophageal conjunctivism (GEJ) cancer, microsatellite high instability (MSI-H) or DNA misalising repair defects (dMMR) endometrial cancer patients, non-small cell lung cancer (NSCLC) and anal squamous cell carcinoma.
    , clinical trials for first-line treatment of NSCLC have entered phase III clinical phase.
    squamous cell carcinoma (SCCA) is a rare tumor that accounts for only 2% of the malignant tumors in the digestive tract.
    estimates that there are about 27,000 new SCCA cases worldwide each year.
    most local early SCCA patients can be cured with chemotherapy, 25% of patients will progress to disease metastasis.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.